Clinical trial · no report yet · Phase 3
SUCCESSOR-1
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT05519085 ↗
- Recruiting
- Celgene
- 44 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 26 | |
| Podcasts | 12 | |
| X threads | 4 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- mezigdomide; Pomalidomide; Bortezomib; Dexamethasone
- Arms
- MeziVd (mezigdomide, bortezomib and dexamethasone) · Experimental
- PVd (pomalidomide, bortezomib and dexamethasone) · Experimental
- Enrollment
- 810 (estimated)
- Primary outcomes
- Progression-free Survival (PFS)
- Sponsor
- Celgene
- Start
- Sep 20, 2022
- Primary completion
- Jan 10, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05519085 · updated Sep 30, 2026